|
|
News Breaks | | | | October 2, 2012 | | 07:10 EDT |  | CRIS | Curis: 1st patient treated in Phase I clinical trial of oral CUDC-101
Curis announced that the first patient has been treated in a Phase I clinical study of an oral formulation of CUDC-101 in patients with advanced and refractory solid tumors. CUDC-101 is a first-in-class small molecule drug candidate that has been designed as an inhibitor of histone deacetylase, or HDAC, epidermal growth factor receptor, or EGFR, and epidermal growth factor receptor 2, or Her2. The initiation of this Phase I clinical trial of an oral formulation of CUDC-101 is an important milestone for Curis. A successful outcome in this Phase I clinical study could greatly expand the potential for CUDC-101 to be further studied in several cancers, including but not limited to non-small cell lung and gastric cancers, where single pathway targeted agents have demonstrated clinical efficacy. | |
|
News For CRIS From The Last 14 Days Check below for free stories on CRIS the last two weeks. |
|
|
| May 10, 2013 | | 07:04 EDT | | CRIS | Curis announces approval of Erivedge in Australia
Curis announced that Erivedge was approved for marketing registration by Australia's Therapeutic Goods Administration for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate. Erivedge is the first licensed treatment in Australia for patients with advanced basal cell carcinoma, a rare form of skin cancer which can be disfiguring, debilitating and even fatal. Curis earned a $4M milestone payment as a result of the TGA's approval of Erivedge and Curis is also entitled to receive royalties on Roche's future net sales of Erivedge in Australia. | |
|
|
|
|
|
|
